方法：2010-01/2012-12来自中山一院眼科和核医学科确诊的Graves眼病患者118例，其中男37例，女81例，年龄14～67(平均35.4±12.2)岁，每天口服15mg泼尼松，连服3～6mo。好转定义为治疗后突眼严重性分级减低和/或突眼由活动变为非活动。于治疗第6mo末比较治疗前后突眼的变化并对疗效的影响因素进行分析。

结果：经泼尼松治疗后，58.5%的 Graves眼病患者突眼好转； 其中72.6% 的活动性突眼患者突眼好转，而非活动性突眼患者仅23.5% 好转，两组差异有统计学意义(P<0.01)。活动性突眼患者血清TRAb高于非活动性患者(P<0.01)。轻中重度三组突眼的患者中，突眼越轻的患者疗效越好(P<0.01)。突眼病程越长，突眼越严重(P<0.01)。治疗期间甲状腺功能状态无论过高或过低，均可加重患者突眼(P<0.01)。

结论：每天口服15mg泼尼松，持续3～6mo对活动性Graves突眼的改善明显优于非活动性突眼。病程越短的患者突眼越轻，而突眼越轻治疗效果越好，故发现突眼需及早治疗，同时力争把甲状腺功能控制在正常范围，减少突眼的加重。

METHODS: We examined the outcome at the end of 6 mo of oral prednisone 15mg daily treatment for Graves' ophthalmopathy in the First Affiliated Hospital of Sun Yat-sen University during the period January 2010 to December 2012. Totally 118 patients ranging in age from 14 to 67 years old(mean 35.4±12.2). There were 37 males and 81 females. We compared the changes of the severity and clinical activity score(CAS)of Graves' ophthalmopathy before and after treatment. We defined clinical effectiveness as the severity assessment improvement and/or clinical activity score improvement from active to non-active. We evaluated the efficacy and influencing factors of Graves' ophthalmopathy treated by oral low dose prednisone.

RESULTS:After treatment, 58.5% patients were improved. The improvement in active patients were 72.6% significantly greater than in non-active patients 23.5%(P<0.01). Serum TRAb in active patients was significantly higher than in non-active patients(P<0.01). Among the severity assessment, less severity patients improved significantly greater than more severity(P<0.01). The longer the course, the more severity the patients(P<0.01). Either hyperthyroid or hypothyroid played a role in the exacerbation, leading to deterioration in patients(P<0.01).

CONCLUSION:Active Graves' ophthalmopathy patients improved greater than non-active patients after received oral prednisone 15mg daily treatment for 3-6 mo. The shorter the course, the milder the patients, and the more effective the treatment. So, we should treat Graves' ophthalmopathy as early as possible, and try our best to keep the patients euthyroid to avoid deterioration.